Intestinal bacterial overgrowth during chronic pancreatitis

Erminio Trespi, Antonella Ferrieri

Research output: Contribution to journalArticle

Abstract

Introduction. The presence of an intestinal bacterial overgrowth (IBO) in patients with pancreatic insufficiency has been recently suggested to justify the worsening of their clinical conditions despite pancreatic enzyme supplementation. Aim. The purpose of this study were (a) to verify IBO frequency in patients with pancreatic insufficiency owing to chronic pancreatitis and (b) to evaluate the effect of chronic administration of a non-absorbable antibiotic, Rifaximin, in reducing IBO frequency and influencing the clinical picture of the disease. Material and Methods. Thirty-five patients with pancreatic insufficiency owing to chronic pancreatitis and 61 gastro-resected patients without pancreatic disease were studied. The presence of IBO was tested in both groups of patients using the hydrogen breath test with glucose. Chronic pancreatitis patients were subsequently treated with Rifaximin, 400 mg t.i.d. for seven consecutive days each month for three months. Results. A positive hydrogen breath test was present in 12 out of 35 (34%) chronic pancreatitis patients and in 13 out 61 (21%) controls (P <0.002). In chronic pancreatitis patients an IBO was most likely to be present in the presence of a high ethanol intake, pancreatic microcalcifications, concomitant gallstones, diarrhoea and a history of gastric resection. In all patients with IBO, Rifaximin administration normalised the hydrogen breath test and reduced symptoms. Conclusions. IBO is frequent in patients with pancreatic insufficiency, particularly in those with a history of gastroduodenal surgery. Treatment with Rifaximin reduces IBO frequency and improves symptoms.

Original languageEnglish
Pages (from-to)47-52
Number of pages6
JournalCurrent Medical Research and Opinion
Volume15
Issue number1
Publication statusPublished - 1999

Fingerprint

Chronic Pancreatitis
rifaximin
Exocrine Pancreatic Insufficiency
Breath Tests
Hydrogen
Calcinosis
Pancreatic Diseases
Gallstones
Diarrhea
Stomach
Ethanol
Anti-Bacterial Agents
Glucose

Keywords

  • Bacterial overgrowth
  • Pancreatitis
  • Rifaximin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Intestinal bacterial overgrowth during chronic pancreatitis. / Trespi, Erminio; Ferrieri, Antonella.

In: Current Medical Research and Opinion, Vol. 15, No. 1, 1999, p. 47-52.

Research output: Contribution to journalArticle

Trespi, Erminio ; Ferrieri, Antonella. / Intestinal bacterial overgrowth during chronic pancreatitis. In: Current Medical Research and Opinion. 1999 ; Vol. 15, No. 1. pp. 47-52.
@article{6ccf974851e1444199e1215ca6f0f2eb,
title = "Intestinal bacterial overgrowth during chronic pancreatitis",
abstract = "Introduction. The presence of an intestinal bacterial overgrowth (IBO) in patients with pancreatic insufficiency has been recently suggested to justify the worsening of their clinical conditions despite pancreatic enzyme supplementation. Aim. The purpose of this study were (a) to verify IBO frequency in patients with pancreatic insufficiency owing to chronic pancreatitis and (b) to evaluate the effect of chronic administration of a non-absorbable antibiotic, Rifaximin, in reducing IBO frequency and influencing the clinical picture of the disease. Material and Methods. Thirty-five patients with pancreatic insufficiency owing to chronic pancreatitis and 61 gastro-resected patients without pancreatic disease were studied. The presence of IBO was tested in both groups of patients using the hydrogen breath test with glucose. Chronic pancreatitis patients were subsequently treated with Rifaximin, 400 mg t.i.d. for seven consecutive days each month for three months. Results. A positive hydrogen breath test was present in 12 out of 35 (34{\%}) chronic pancreatitis patients and in 13 out 61 (21{\%}) controls (P <0.002). In chronic pancreatitis patients an IBO was most likely to be present in the presence of a high ethanol intake, pancreatic microcalcifications, concomitant gallstones, diarrhoea and a history of gastric resection. In all patients with IBO, Rifaximin administration normalised the hydrogen breath test and reduced symptoms. Conclusions. IBO is frequent in patients with pancreatic insufficiency, particularly in those with a history of gastroduodenal surgery. Treatment with Rifaximin reduces IBO frequency and improves symptoms.",
keywords = "Bacterial overgrowth, Pancreatitis, Rifaximin",
author = "Erminio Trespi and Antonella Ferrieri",
year = "1999",
language = "English",
volume = "15",
pages = "47--52",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Intestinal bacterial overgrowth during chronic pancreatitis

AU - Trespi, Erminio

AU - Ferrieri, Antonella

PY - 1999

Y1 - 1999

N2 - Introduction. The presence of an intestinal bacterial overgrowth (IBO) in patients with pancreatic insufficiency has been recently suggested to justify the worsening of their clinical conditions despite pancreatic enzyme supplementation. Aim. The purpose of this study were (a) to verify IBO frequency in patients with pancreatic insufficiency owing to chronic pancreatitis and (b) to evaluate the effect of chronic administration of a non-absorbable antibiotic, Rifaximin, in reducing IBO frequency and influencing the clinical picture of the disease. Material and Methods. Thirty-five patients with pancreatic insufficiency owing to chronic pancreatitis and 61 gastro-resected patients without pancreatic disease were studied. The presence of IBO was tested in both groups of patients using the hydrogen breath test with glucose. Chronic pancreatitis patients were subsequently treated with Rifaximin, 400 mg t.i.d. for seven consecutive days each month for three months. Results. A positive hydrogen breath test was present in 12 out of 35 (34%) chronic pancreatitis patients and in 13 out 61 (21%) controls (P <0.002). In chronic pancreatitis patients an IBO was most likely to be present in the presence of a high ethanol intake, pancreatic microcalcifications, concomitant gallstones, diarrhoea and a history of gastric resection. In all patients with IBO, Rifaximin administration normalised the hydrogen breath test and reduced symptoms. Conclusions. IBO is frequent in patients with pancreatic insufficiency, particularly in those with a history of gastroduodenal surgery. Treatment with Rifaximin reduces IBO frequency and improves symptoms.

AB - Introduction. The presence of an intestinal bacterial overgrowth (IBO) in patients with pancreatic insufficiency has been recently suggested to justify the worsening of their clinical conditions despite pancreatic enzyme supplementation. Aim. The purpose of this study were (a) to verify IBO frequency in patients with pancreatic insufficiency owing to chronic pancreatitis and (b) to evaluate the effect of chronic administration of a non-absorbable antibiotic, Rifaximin, in reducing IBO frequency and influencing the clinical picture of the disease. Material and Methods. Thirty-five patients with pancreatic insufficiency owing to chronic pancreatitis and 61 gastro-resected patients without pancreatic disease were studied. The presence of IBO was tested in both groups of patients using the hydrogen breath test with glucose. Chronic pancreatitis patients were subsequently treated with Rifaximin, 400 mg t.i.d. for seven consecutive days each month for three months. Results. A positive hydrogen breath test was present in 12 out of 35 (34%) chronic pancreatitis patients and in 13 out 61 (21%) controls (P <0.002). In chronic pancreatitis patients an IBO was most likely to be present in the presence of a high ethanol intake, pancreatic microcalcifications, concomitant gallstones, diarrhoea and a history of gastric resection. In all patients with IBO, Rifaximin administration normalised the hydrogen breath test and reduced symptoms. Conclusions. IBO is frequent in patients with pancreatic insufficiency, particularly in those with a history of gastroduodenal surgery. Treatment with Rifaximin reduces IBO frequency and improves symptoms.

KW - Bacterial overgrowth

KW - Pancreatitis

KW - Rifaximin

UR - http://www.scopus.com/inward/record.url?scp=0032962971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032962971&partnerID=8YFLogxK

M3 - Article

C2 - 10216811

VL - 15

SP - 47

EP - 52

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 1

ER -